XJPX
7090
Market cap6mUSD
Jul 10, Last price
769.00JPY
1D
0.00%
1Q
-23.25%
IPO
-47.15%
Name
Ligua Inc
Chart & Performance
P/E
—
P/S
0.45
EPS
—
Div Yield, %
—
Shrs. gr., 5y
1.23%
Rev. gr., 5y
-2.08%
Revenues
2.42b
-15.77%
Net income
-241m
L-19.92%
CFO
264m
+61.39%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Ligua Inc., founded in Osaka, Japan in 2004, operates as a consulting firm primarily offering management support services within the healthcare sector. The company's activities are structured across two main divisions: Orthopedic Clinic Solutions and Financial Services. In its Orthopedic Clinic Solutions segment, Ligua develops and provides specialized software, such as Ligoo POS & CRM for managing patient information in osteopathic clinics, and ReceONE, a system designed for calculating receipts for health insurance claim submissions. This division also supplies a variety of medical devices and supplies, including EMS-indepth-, an electrical muscle stimulation unit; the Thomson bed, a hydraulic-electric treatment table used for addressing pelvic and spinal misalignments; Inject Energy, a low-frequency treatment device aimed at alleviating deep tissue pain and improving muscle atrophy; and Dr.Supporter, a general medical device utilizing Integrated Functional Mineral Crystal technology to enhance blood circulation, promote fatigue recovery, ease muscle soreness and stiffness, relieve neuralgia and lower back pain, and support core strength. Furthermore, it delivers educational training consulting, including tailored programs and online client attraction strategies for orthopedic clinics, alongside medical expense billing agency services. Ligua's Financial Services arm is involved in insurance agency activities, financial instrument intermediation, and offers financial advisory services, including mediation for mergers and acquisitions, to a diverse range of businesses.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||